Please login to the form below

Not currently logged in
Email:
Password:

tasimelteon

This page shows the latest tasimelteon news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -

Latest news

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... Tasimelteon acts on melatonin MT1/MT2 receptors and

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics